Cyclacel Pharmaceuticals Inc (CYCCP.OQ)
17 Feb 2017
Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.
Feb 23 Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.
Feb 23 Cyclacel Pharmaceuticals Inc said its experimental drug failed in a late-stage study on patients aged 70 years or more with newly diagnosed acute myeloid leukemia.
* Cyclacel announces top-line results from pivotal phase 3 seamless study in elderly patients with acute myeloid leukemia
* Intra-Cellular Therapies Inc- on January 4, 2017, co's unit entered into a supply agreement with Siegfried Evionnaz SA- SEC filing Source: (http://bit.ly/2jALlxx) Further company coverage:
* Cyclacel pharmaceuticals reports 3rd quarter 2016 financial results
* Intra-Cellular Therapies reports third quarter 2016 financial results and provides corporate update
Source text - http://bit.ly/2cDs1vi Further company coverage:
* Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2c1aXOy) Further company coverage:
|Takeda Pharmaceutical Co Ltd (4502.T)||¥5,337||+2.00|
|DAIICHI SANKYO COMPANY, LIMITED (4568.T)||¥2,598||+25.50|
|Eisai Co., Ltd (4523.T)||¥6,241||+44.00|
|Pfizer Inc. (PFE.N)||$33.59||-0.03|
|Johnson & Johnson (JNJ.N)||$119.52||-0.14|
|Merck & Co., Inc. (MRK.N)||$65.29||-0.19|
|Roche Holding Ltd. (ROG.S)||CHF244.90||-1.40|
|Roche Holding Ltd. (RO.S)||CHF248.40||-1.50|
|Bayer AG (BAYGn.DE)||€107.90||--|
|Bayer AG (BAYE.F)||--||--|